Please assess the completion status of the following clinical trial:

Trial Title: Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow up.~2. Age ≥ to 75 years old~3. Patient with metastatic cancer among renal cell carcinoma, non small cell lung cancer, pancreatic neuroendocrine cancer, sarcoma , ovarian cancer , thyroid cancer, bladder cancer or breast cancers, who cannot receive any treatment with curative intent.~4. WHO PS ≤ 2,~5. Life expectancy ≥ 3 months,~6. Group 2 (vulnerable) according to SIOG classification,~7. Adequate organ system function as defined in provided Table~Exclusion Criteria:~1. Patient with a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma with PSA \<1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed at low risk for recurrence by his/her treating physician,~2. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug.~3. Criteria of group 3 according to SIOG classification,~4. Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:~   •Active peptic ulcer disease~   •Known intraluminal metastatic lesion/s with risk of bleeding~   •Inflammatory bowel disease (e.g. ulcerative colitis, crohn's disease), or other gastrointestinal conditions with increased risk of perforation~   •History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment.~5. Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:~   •Malabsorption syndrome~   •Major resection of the stomach or small bowel.~6. Presence of uncontrolled infection.~7. Corrected QT interval (QTc) \> 480 msecs using Bazett's formula~8. Anti-coagulants treatment (preventive or curative)~9. History of any one or more of the following cardiovascular conditions within the past 6 months:~   • Cardiac angioplasty or stenting~   • Myocardial infarction~   • Unstable angina~   • Coronary artery bypass graft surgery~  * Symptomatic peripheral vascular disease~  * Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)~10. Poorly controlled hypertension~11. History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.~12. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer~13. Evidence of active bleeding or bleeding diathesis.~14 Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels~15. Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug.~16. Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.~17. Unable or unwilling to discontinue use of prohibited medications list in Appendix 7 for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study~18. Treatment with any of the following anti-cancer therapies:~* radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR~* chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib~  19. Any ongoing toxicity from prior anti-cancer therapy that is \>Grade 1 and/or that is progressing in severity, except alopecia.~  20. Patient not affiliated with social system in France.~  21. Patient deprived of liberty or under guardianship

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib (Type: EXPERIMENTAL): Pazopanib : 3 dose levels are defined : 400, 600 and 800 mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues